TSO3 — Shareholder Meeting (May 2014)
56 slides from TSO3's shareholder meeting presentation, May 7, 2014
Slide 1: Annual General Meeting of the Shareholders
May 7, 2014 Annual General Meeting of the Shareholders
Slide 2: Germain Carrière, Chairman of the Board
2 Germain Carrière Chairman of the Board
Slide 3: Agenda of the Meeting
Agenda of the Meeting 3 Order of the day Appointment of secretary and scrutineer Verification of the validity of the Meeting Conformity of deadline of Notice Quorum General Meeting Financial Results for the period ended December 31, 2013, by Benoît Deschamps, CFO Appointment of Direc
Slide 4: Annual General Meeting of the Shareholders
May 7, 2014 Annual General Meeting of the Shareholders
Slide 5: Benoît Deschamps, Financial Results
5 Benoît Deschamps Chief Financial Officer Financial Results - Period ended December 31, 2013
Slide 6: Financial Highlights – Fiscal year 2013
Financial Highlights – Fiscal year 2013 6 Year ‐ 2013 Year ‐ 2012 In thousands dollars $ $ As reported, accounting for One-Line Items Total Revenues 254 2 854 Total Expenses (9 525) (8 649) Total Loss (9 271) (5 795) Loss Per Share (0,13) (0,09) Excluding One-Line Items Total Revenues 254 1 268 Tota
Slide 7: Highlights - Q1 2014
Highlights - Q1 2014 7 In thousands dollars $ $ As reported Revenues 82 76 Net Loss 1 561 2 100 Net Loss Per Share 0,02 0,03 Excluding Additionnal R&D Tax Credits Revenues 82 76 Net Loss 1 798 2 100 Net Loss Per Share 0,02 0,03
Slide 8: Revenue Retrospective
Revenue Retrospective 8 In thousands dollars In thousands dollars 2,500 4,000 3,500 2,000 3,000 1,500 2,500 2,000 1,000 1,500 1,000 500 500 - - Q1-2010 Q2-2010 Q3-2010 Q4-2010 Q1-2011 Q2-2011 Q3-2011 Q4-2011 Q1-2012 Q2-2012 Q3-2012 Q4-2012 Q1-2013 Q2-2013 Q3-2013 Q4-2013 Q1-2014 2010 2011 2012 2013
Slide 9: Expenses Retrospective
Expenses Retrospective 9 In thousands dollars In thousands dollars 4,500 12,000 4,000 10,000 3,500 3,000 8,000 2,500 2,000 6,000 1,500 4,000 1,000 500 2,000 - - Q1-2010 Q2-2010 Q3-2010 Q4-2010 Q1-2011 Q2-2011 Q3-2011 Q4-2011 Q1-2012 Q2-2012 Q3-2012 Q4-2012 Q1-2013 Q2-2013 Q3-2013 Q4-2013 Q1-2014 (50
Slide 10: Financial Results
Financial Results 10 In In Q1-2010 Q2-2010 Q3-2010 Q4-2010 Q1-2011 Q2-2011 Q3-2011 Q4-2011 Q1-2012 Q2-2012 Q3-2012 Q4-2012 Q1-2013 Q2-2013 Q3-2013 Q4-2013 Q1-2014 thousands thousands dollars dollars 2010 2011 2012 2013 0 0 -500 -1,000 -2,000 -1,000 -3,000 -1,500 -4,000 -2,000 -5,000 -2,500 -6,000 -7
Slide 11: Cash Burn Rate
Cash Burn Rate 11 1,400 In thousands dollars In thousands dollars 2010 2011 2012 2013 1,200 - 1,000 36-month (2,000) average 800 burn rate of $642,408 600 2013 (4,000) average burn rate of 400 $615,644 (6,000) 200 0 (8,000) (10,000) Burn Rate - Actual Burn Rate - Actual Burn Rate - Adjusted for unus
Slide 12: Financial Condition - Runway
Financial Condition - Runway 12 Liquidities at December 31, 2013: $9,609,000 March 31, 2014: $8,980,000 $ 12,000,000 10,000,000 8,000,000 6,000,000 4,000,000 2,000,000 0 36-month burn rate of $642,000 Q1-2014 adjusted burn rate of $550,000
Slide 13: Agenda of the Meeting
Agenda of the Meeting 13 Order of the day Appointment of secretary and scrutineer Verification of the validity of the Meeting Conformity of deadline of Notice Quorum General Meeting Financial Results for the period ended December 31, 2013, by Benoît Deschamps, CFO Appointment of Dire
Slide 14: Annual General Meeting of the Shareholders
May 7, 2014 Annual General Meeting of the Shareholders
Slide 15: R.M. (Ric) Rumble, President and CEO
15 R.M. (Ric) Rumble President and Chief Executive Officer
Slide 16: Forward-looking Information
Forward-looking Information 16 The speeches made during this meeting may include forward-looking information with respect to the Company, including its business operations, strategy, financial performance and condition. Although management of the Corporation believes that the conclusions, estimates
Slide 17: Our Vision
Our Vision 17 Creating the Improved Standard in Healthcare Sterile Reprocessing
Slide 18: Key Historic Events
Key Historic Events 18 1998-2008 • Initial sterilization platform (limitations in offering as per cycle times and compatibility) Regulatory clearance in Canada and the United States Sold directly by TSO3 with limited success (38 units/5 years) 2009-2010 • Renewed direction • Second generation st
Slide 19: Where we have come from / Where we are
Where we have come from / Where we are 19 TSO3 Files for Commercial Clearance in the United States - June 30, 2011 - TSO3 resubmits documents to De Novo proceed with US regulatory clearance 510(k) - April 20, 2012 - TSO3 Files New and Simplified TSO3 and 3M agree to global Submission to the US chann
Slide 20: FDA ...Why so long?
FDA ...Why so long? 20 510(k) process: Compare new device to an existing legally cleared device Challenge: Introduce “innovation” while demonstrating “similar” to existing device 2009 – 2010 Changes in the Guidance document Not Substantial Equivalent (NSE) based on predicate 2011- 2013 Mec
Slide 21: USA Regulatory Strategy
USA Regulatory Strategy 21 New 510(k) Submission Incorporating previously substantiated data and Data collected on our Device and Predicates as guided by the US Regulatory Authorities in the January 2014 response
Slide 22: FDA ...Why so long?
FDA ...Why so long? 22 STERIZONE® VP4 Sterilizer USA only Similar but DIFFERENT from REST OF THE WORLD Sterilizer One Cycle Broadest claim, largest load in industry Relies solely on Hydrogen Peroxide as active Sterilant Elevated H2O2 MEC Utilizes Ozone to remove residual H202 Remov
Slide 23: Comparison of STERIZONE 125L+ and VP4 Sterilizers
Comparison of 23 STERIZONE® 125L+ and VP4 Sterilizers STERIZONE® 125L+ Sterilizer (1) STERIZONE® VP4 Sterilizer (2) Cycle 1 Cycle 2 Cycle 3 Single channel flexible endoscopes Inside diameter of 1.0 mm or larger and length of 850 mm or shorter Cycle Time 46 56 100 (minutes) Application Single-chann
Slide 24: What differentiates TSO3
What differentiates TSO3 24 Predicate Devices Parameters STERIZONE® 100NX 100NX 100NX 100NX V-PRO maX V-PRO maX V-PRO maX VP4 cycle Standard Flex Scope EXPRESS DUO cycle Flex Scope Lumen Non cycle cycle cycle cycle cycle Lumen cycle Maximum 75 lb load weight (+ 25 lb 21.4 lb 21.4 lb 10.7 lb 13.2 lb
Slide 25: What differentiates TSO3
What differentiates TSO3 25 Predicate Devices Broad Sterilization Claims Parameters STERIZONE® 100NX 100NX 100NX 100NX V-PRO maX V-PRO maX V-PRO maX VP4 cycle Standard Flex Scope EXPRESS DUO cycle Flex Scope Lumen Non cycle cycle cycle cycle cycle Lumen cycle Maximum 75 lb load weight (+ 25 lb 21.4
Slide 26: What differentiates TSO3
What differentiates TSO3 26 Broad Sterilization Claims Parameters STERIZONE® 100NX 100NX 100NX 100NX V-PRO maX V-PRO maX V-PRO maX VP4 cycle Standard Flex Scope EXPRESS DUO cycle Flex Scope Lumen Non cycle cycle cycle cycle cycle Lumen cycle Maximum 75 lb load weight (+ 25 lb 21.4 lb 21.4 lb 10.7 lb
Slide 27: What differentiates TSO3
What differentiates TSO3 27 Predicate Devices Predicate Devices offer multiple cycles which are both instrument and load size restricted Parameters STERIZONE® 100NX 100NX 100NX 100NX V-PRO maX V-PRO maX V-PRO maX VP4 cycle Standard Flex Scope EXPRESS DUO cycle Flex Scope Lumen Non cycle cycle cycle
Slide 28: What differentiates TSO3
What differentiates TSO3 28 Predicate Devices Predicate Devices offer multiple cycles which are both instrument and load size restricted Parameters STERIZONE® 100NX 100NX 100NX 100NX V-PRO maX V-PRO maX V-PRO maX VP4 cycle Standard Flex Scope EXPRESS DUO cycle Flex Scope Lumen Non cycle cycle cycle
Slide 29: Both Sterilizers are covered by existing and planned patent coverage
Both the STERIZONE® 125L+ and the VP4 Sterilizers are covered by existing and planned patent coverage 29 Patent US Publication Filing date Title Implemented Implemented Scope of the protection sought Application Number in 125L+ in VP4 in the outside US? US? Original 2011/0076192 29/09/2010 Steriliza
Slide 30: What makes us better?
What makes us better? 30 While others offer either/or the following benefits: Efficacy and compatibility Loading capacity Speed We combine them all, allowing for: Increased throughput Lowest cost Our solution can replace multiple sterilization technologies
Slide 31: In Summary
In Summary 31 The STERIZONE® 125L+ and the STERIZONE® VP4 Sterilizers offer protected, rapid cycle time, efficacious, device compatible sterilization, with the highest loading capacity, providing the lowest delivered cost per instrument sterilized
Slide 32: The Opportunity
32 The Opportunity Increasing demand for low temperature sterile reprocessing
Slide 33: Growing Population
Growing Population 33 17% increase 7.9% increase 2010 2020 More people = more surgeries Annals of Surgery. 2003 August; 238(2): 170‐177.
Slide 34: Aging Population
Aging Population 34 50% increase 2 billion 605 million 2000 2050 60 yrs+ is the fastest growing segment Individuals 65 yrs+ consume majority of OR time 34 World Health Organization (WHO)
Slide 35: Increase in Surgeries… Some data
Increase in Surgeries… Some data 35 48 million surgical procedures were performed in the U.S. alone in 2009. Global cardio-thoracic MIS procedures were around 10 million in 2011, estimated to reach 14 million by 2016. There were 9 million gastrointestinal procedures in 2011, estimated to reach
Slide 36: Advancement in Surgical Techniques
Advancement in Surgical Techniques… (Minimally Invasive Surgeries - MIS) 36 Neurosurgery Orthopaedics Pulmonary Medicine Cardiology MIS Gynaecology Gastroenterology Urology …demands development of low temperature sterilization technologies
Slide 37: Rise in Hospital-Acquired Infections (HAI)
Rise in Hospital-Acquired Infections (HAI) 37 At any given time in every 1 20 infections is related to hospital care in the U.S. alone. Cost of HAI to be absorbed by health care institutions US Department of Health & Human Services
Slide 38: Even more evidence…
Even more evidence… 38 Three out of 20 gastrointestinal scopes improperly cleaned, contaminated with “Bio Dirt” June 9, 2013 Source: Bommarito M, Thornhill G, Morse D. A Multi-site Field Study Evaluating the Effectiveness of Manual Cleaning of Flexible Endoscopes with an ATP Detection System. Amer
Slide 39: Initial Target: Hospital Sterile Reprocessing
Initial Target: Hospital Sterile Reprocessing 39 #2 OR OR OR OR OR #1 CS Operating Room Department (OR) OR OR OR OR Central Sterilization (CS) OR Reprocessing and Sterile Storage #3 GI Gastroenterology Department (GI) 39
Slide 40: Market Opportunity
Market Opportunity 40 CS Worldwide Installed Base Capital Equipment $4.5 billion (installed base) $450 million annually Consumables US $250 million annually Canada OR Capital Equipment Europe $600 million in North America only (7,500 units) ROW Defined Large Growing Frost & Sulliva
Slide 41: Accelerated Growth
Accelerated Growth 41 Transparency Market Research 2013 Sterilization and disinfection devices from $5.13bn to $9.15bn 2013-2019 (CAGR @ 8.5%) Low Temperature Sterilization fastest growth segment Projected at 10.9% during the forecasted period
Slide 42: Key Strategic Initiatives
42 Key Strategic Initiatives
Slide 43: Winning… “Defined”
Winning… “Defined” 43 FDA clearance… Channel partner… Increased portfolio…
Slide 44: Winning… “Defined”
Winning… “Defined” 44 FDA clearance... Channel partner... Increased portfolio... Products STERIZONE® 80L Sterilizer Enhanced cycles Pass through systems
Slide 45: Partnership Discussions
Eee Partnership Discussions
Slide 46: User Experience
User Experience 46 Significantly decreasing (when not eliminating) the use of other methods such as liquid chemicals and toxic ethylene oxide Using two as it is the preferred method (i.e. back-up system is one of the same) - some already planning to purchase additional units Improving standard
Slide 47: Channel Partner – History and Approach
Channel Partner – History and Approach 47 2009-2012 Signed agreement with 3M in December 2009 for the exclusive supply, distribution, license and service of the new STERIZONE® 125L+ Sterilizer. On June 15, 2012 TSO3 exercised right to terminate the agreement, as provided by the agreement; Sett
Slide 48: Channel Strategy
Channel Strategy 48 What makes a good partner? Global in scope Hungry: They commit their time and resources Capable: Direct Sales and Service Bundle: The ability to create “sterilization rooms” We fill a “GAP” in their portfolio: Bolt-on product acquisition Speed to market opportunit
Slide 49: Increase the Portfolio
49 Increase the Portfolio
Slide 50: Increase the Portfolio
Increase the Portfolio 50 STERIZONE® 80L Sterilizer • OR sub-sterile • Emerging markets Enhanced cycles • Faster • Gentler Pass through systems • Dirty to Clean
Slide 51: Financial Condition - Runway
Financial Condition - Runway 51 2009-12-16 2011-06-30 Agreement with 3M 2.5 Re-Submission 2009-12-29 with FDA FDA Filiing and CE Mark 2012-08-02 2 Terminaison of 3M Agreement Announced 1.5 2009-09-02 LOI with 3M 2010-06-08 1 NSE Letter 2013-01-28 0.5 Clean-up 510(k) file submitted 0 December 31, 2
Slide 52: Conserving Resources
Conserving Resources 52 Collective dismissal – Conserve resources It was our choice to conserve resources vs. raise capital Impact Minimized dilution Focused efforts on FDA clearance Monthly Burn Rate Historical $640,000 Runway available + 1 year Activities negatively impacted Ne
Slide 53: Transition
Transition 53 New directions 2014 is the transitional year for the Company Focus on FDA clearance Create the channel partner strategy to be employed post clearance Only then: Deliver the planned path forward for Shareholder support and milestone measurement
Slide 54: Questions
Questions 54 When should we expect the FDA Clearance? Answer: We cannot predict the timing of the clearance, rather we can say that the Agency has a total of 90 days to review the file and if they have questions TSO3 will have a total of 180 days to respond. If TSO3 does not obtain the FDA, do y
Slide 55: Questions
Questions 55 Does the Company’s Intellectual Property cover the new STERIZONE® VP4 Sterilizer? Answer: Yes please refer to slide 29 which describes the protection of each sterilizer. By removing the 1.1mm X 3.5m multi-channel device claim in the STERIZONE® VP4 Sterilizer do we lose part of our v
Slide 56: Annual General Meeting of the Shareholders
May 7, 2014 Annual General Meeting of the Shareholders